JP2019517508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517508A5 JP2019517508A5 JP2018563076A JP2018563076A JP2019517508A5 JP 2019517508 A5 JP2019517508 A5 JP 2019517508A5 JP 2018563076 A JP2018563076 A JP 2018563076A JP 2018563076 A JP2018563076 A JP 2018563076A JP 2019517508 A5 JP2019517508 A5 JP 2019517508A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pharmaceutical composition
- cell receptor
- medicine
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022132995A JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760 | 2016-06-02 | ||
| EP16172760.7 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022132995A Division JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517508A JP2019517508A (ja) | 2019-06-24 |
| JP2019517508A5 true JP2019517508A5 (https=) | 2020-07-16 |
| JP7321709B2 JP7321709B2 (ja) | 2023-08-07 |
Family
ID=56132759
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563076A Active JP7321709B2 (ja) | 2016-06-02 | 2017-06-02 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
| JP2022132995A Pending JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022132995A Pending JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (https=) |
| EP (2) | EP4253419A3 (https=) |
| JP (2) | JP7321709B2 (https=) |
| AU (1) | AU2017275782B2 (https=) |
| CA (1) | CA3026172A1 (https=) |
| CY (1) | CY1126489T1 (https=) |
| DK (1) | DK3463436T3 (https=) |
| ES (1) | ES2965957T3 (https=) |
| FI (1) | FI3463436T3 (https=) |
| HR (1) | HRP20231650T1 (https=) |
| HU (1) | HUE065176T2 (https=) |
| LT (1) | LT3463436T (https=) |
| PL (1) | PL3463436T3 (https=) |
| PT (1) | PT3463436T (https=) |
| RS (1) | RS65007B1 (https=) |
| SI (1) | SI3463436T1 (https=) |
| WO (1) | WO2017207814A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2536830T3 (pl) | 2010-02-16 | 2020-02-28 | Ultimovacs As | Polipeptydy |
| EP4253419A3 (en) | 2016-06-02 | 2024-05-22 | Ultimovacs ASA | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| GB201803178D0 (en) * | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| TWI805792B (zh) * | 2018-06-29 | 2023-06-21 | 日商大鵬藥品工業股份有限公司 | 抗腫瘤劑及其評估方法 |
| US20250152688A1 (en) | 2021-06-09 | 2025-05-15 | Ultimovacs Ab | A Conjugate |
| WO2024083866A1 (en) | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Cancer treatment |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5004390B2 (ja) | 1999-08-23 | 2012-08-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 新規ｂ７−４分子およびその用途 |
| DK1234031T3 (en) | 1999-11-30 | 2017-07-03 | Mayo Foundation | B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE |
| NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2536830T3 (pl) | 2010-02-16 | 2020-02-28 | Ultimovacs As | Polipeptydy |
| LT2547364T (lt) | 2010-03-15 | 2017-03-27 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Peptidai, konjugatai ir vakcinos imunogeniškumo padidinimo būdas |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| US9561266B2 (en) | 2012-08-31 | 2017-02-07 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| US9974845B2 (en) * | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| KR20150130284A (ko) | 2013-03-15 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 백신 및 이를 이용한 치료 방법 |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| US20170035864A1 (en) | 2013-12-09 | 2017-02-09 | Bullet Biotechnology, Inc. | SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| WO2015096811A1 (zh) | 2013-12-27 | 2015-07-02 | 厦门松霖科技有限公司 | 暗装预埋组件 |
| ES2738582T3 (es) | 2014-02-14 | 2020-01-23 | Immune Design Corp | Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica |
| WO2015128313A1 (en) | 2014-02-25 | 2015-09-03 | Deutsches Krebsforschungszentrum | Rna viruses for immunovirotherapy |
| KR102499737B1 (ko) | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
| ES2851451T3 (es) | 2014-05-13 | 2021-09-07 | Bavarian Nordic As | Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3 |
| US20170136127A1 (en) | 2014-07-01 | 2017-05-18 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| EP3169355A4 (en) | 2014-07-18 | 2018-07-25 | Advaxis, Inc. | Listeria-based immunogenic compositions for eliciting anti-tumor responses |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| WO2016063263A2 (en) | 2014-10-23 | 2016-04-28 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| US11236139B2 (en) | 2014-11-05 | 2022-02-01 | The Regents Of The University Of California | Combination immunotherapy |
| MX2018008797A (es) | 2016-01-19 | 2018-11-29 | Pfizer | Vacunas contra el cancer. |
| EP4253419A3 (en) | 2016-06-02 | 2024-05-22 | Ultimovacs ASA | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
-
2023
- 2023-12-19 CY CY20231100756T patent/CY1126489T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517508A5 (https=) | ||
| AU2018250464B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| TWI796299B (zh) | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 | |
| JP2021100956A (ja) | インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 | |
| CA2934073A1 (en) | Combination therapy with neoantigen vaccine | |
| EP3666793A3 (en) | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 | |
| JP2018183174A (ja) | 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ | |
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| KR20160044035A (ko) | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 | |
| KR20170045240A (ko) | 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도 | |
| US20170021039A1 (en) | Cancer Therapy | |
| Fisher et al. | Neoadjuvant anti-tumor vaccination prior to surgery enhances survival | |
| Hou et al. | C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy | |
| Parums | Status of immune therapy in non-small cell lung cancer (NSCLC) | |
| RU2020117746A (ru) | Иммунотерапевтические способы лечения и/или профилактики рака легких |